Program
EDP167
A development code. Also written as “EDP167 100mg”, “EDP167 200mg” and “EDP167 300mg”.
Its studies are mostly in Dyslipidemias · Homozygous Familial Hypercholesterolemia, led by Eddingpharm (Zhuhai).
Furthest: phase 2, since Mar 19, 20263 company-led studies, 2 open or runningNext primary completion: Nov 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eddingpharm (Zhuhai) | 32 open or running | phase 2since Mar 19, 2026 | Feb 2, 2026 | Nov 2027phase 2 · NCT07799129 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 2, 2026First study: phase 1 study in DyslipidemiasFirst studyNCT07412080 · 40 enrolled · China
- Mar 19, 2026Phase 2 study in Homozygous Familial HypercholesterolemiaPhase 2 reachedNCT07489209 · 20 planned · China
- Aug 27, 2026Phase 2 study in DyslipidemiasNCT07799129 · 144 planned · China
Ahead
- Nov 2027Primary completion: phase 2 study in DyslipidemiasNCT07799129
TargetBeta
ANGPTL3 →read by rule
“EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions.”study text, by rule · the study
Other programs on ANGPTL3
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07799129Dyslipidemias · China | 2 | Not yet recruiting | Nov 2027 | 144 |
| NCT07489209Homozygous Familial Hypercholesterolemia · China | 2 | Recruiting | Oct 4, 2026 | 20 |
| NCT07412080Dyslipidemias · China | 1 | Completed | Dec 12, 2025 | 40 |
How it is read
Names in the registry
- “EDP167”, 2 entries
- “EDP167 100mg”, 1 entry
- “EDP167 200mg”, 1 entry
- “EDP167 300mg”, 1 entry
Codes read as this program: EDP167.
Conditions, from the studies’ own filings
- Dyslipidemias, 2 studies
- Homozygous Familial Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.